Study of Cryoablation for Metastatic Lung Tumors


About this study

The purpose of this study is to evaluate the safety and efficacy of cryoablation therapy used to treat tumors in patients with pulmonary metastatic disease. This study is to enroll patients who will undergo cryoablation of at least 1 metastatic pulmonary tumor that is less than or equal to 3.5cm. Patients will be followed 24 months post their cryoablation procedure.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patient must be at least 18 years old.
  • Patient has signed a written informed consent.
  • Patient presents with Stage 4 pulmonary metastatic disease with metastatic disease previously confirmed by prior biopsy; or Patient presents with Stage 4 pulmonary metastatic disease previously confirmed on imaging (e.g. computerized tomography or CT) with histology proven primary cancer.
  • Patient has up to 6 local pulmonary metastases targetable by cryoablation.
  • Targeted index tumor(s) defined as intra pulmonary or pleural with a maximum size of 3.5 cm, measured in the longest cross sectional dimension.
  • The target index tumor(s) is determined (by CT images) to be in a location where cryoablation is technically achievable based on the proximity of adjacent organs/ structures and is greater than 0.5 cm from any critical organ/structure (possibly achieved with additional maneuvers such as iatrogenic pneumothorax or hydrodissection).
  • Karnofsky Performance Scale (KPS) score greater than or equal to 60.
  • Platelet count greater than 50,000/mm3 within 8 weeks prior to initial cryoablation procedure.
  • International Normalized Ratio (INR) less than 1.5 within 8 weeks prior to initial cryoablation procedure.
  • Patient has a life expectancy of greater than 3 months.

Exclusion Criteria:

  • Patient's index tumor(s) is primary lung cancer.
  • Patient has uncontrollable primary or metastatic disease outside of the lung.
  • Patient is unable to lie flat or has respiratory distress at rest.
  • Patient has a coagulopathy or bleeding disorder which is uncontrolled.
  • Absolute Neutrophil Count (ANC) <1000 within 8 weeks prior to initial cryoablation procedure.
  • Patient has evidence of active systemic, pulmonary, or pericardial infection.
  • Patient has a debilitating medical or psychiatric illness that would preclude giving informed consent or receiving optimal treatment or follow up.
  • Patient is currently participating in other experimental studies that could affect the primary endpoint (e.g. experimental chemotherapy regimen).

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Matthew Callstrom, M.D., Ph.D.

Closed for enrollment

More information


Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions